ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

ClinicalTrials.gov ID: NCT01327612

Public ClinicalTrials.gov record NCT01327612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

Study identification

NCT ID
NCT01327612
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
12 participants

Conditions and interventions

Interventions

  • Bevacizumab Biological
  • Conatumumab Biological
  • Ganitumab Biological
  • Modified FOLFOX6 Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2011
Primary completion
Feb 4, 2020
Completion
Feb 4, 2020
Last update posted
Feb 20, 2021

2011 – 2020

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Research Site Duarte California 91010
Research Site La Jolla California 92093-0957
Research Site Denver Colorado 80218
Research Site Tampa Florida 33612
Research Site Ann Arbor Michigan 48109
Research Site Buffalo New York 14263
Research Site Memphis Tennessee 38120
Research Site Houston Texas 77030
Research Site San Antonio Texas 78229
Research Site Ogden Utah 84403

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01327612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01327612 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →